To include your compound in the COVID-19 Resource Center, submit it here.

Taysha: Applying AAV9 across the CNS

Taysha is leveraging the experience of former AveXis executives to develop AAV9 gene therapies

Taysha launched with a $30 million seed round and a team of former AveXis leaders ready to parlay their experience with Zolgensma into a broad pipeline of AAV9-based gene therapies for other CNS disorders.

The company spun out of the University of Texas Southwestern Medical Center with a pipeline of 15 gene therapy programs, an option to four more and an ongoing partnership with UT Southwestern.

CEO R.A. Session II told BioCentury the focus of those 19 initial programs is

Read the full 791 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers